For heavily treatment-experienced adults with HIV-1 failing therapy. See Full Indication.

Access the resources below for additional details about RUKOBIA, including the challenges of people living with multidrug-resistant (MDR) HIV-1 who are failing their current therapy, its mechanism of action, information about the BRIGHTE trial, dosing and drug interactions, and the full Prescribing Information.

BRIGHTE Long-Term Data for RUKOBIA

~5-Year* Efficacy Results

Hear from Dr. Tony Mills on the exciting long-term data for RUKOBIA

*Based on BRIGHTE 240-week data. 

RUKOBIA NATIONAL BROADCAST

On the panel are Dr. Bruce Gilliam, Dr. Max Lataillade, Dr. Anthony Mills, and Dr. Charlotte-Paige Rolle.

On the panel are Dr. Bruce Gilliam, 
Dr. Max Lataillade, Dr. Anthony Mills, 
and Dr. Charlotte-Paige Rolle.

Virologic Data

See what panelists have to say about efficacy and safety data and what it could mean for people living with MDR HIV-1

Development of RUKOBIA

Hear a story of innovation, in which scientists discover a novel way to treat HIV in people living with MDR HIV-1

PEOPLE LIVING WITH MDR HIV-1 

Get an overview of factors that define the people living with MDR HIV-1 and what might be causing multidrug resistance             

Immunological Response

Watch practicing clinicians talk about CD4+ T-cell recovery in people living with MDR HIV-1 with advanced immunosuppression

BRIGHTE Educational Series

INTRODUCTION TO PEOPLE LIVING WITH MDR HIV-1 

Consider challenges faced by people living with multidrug-resistant (MDR) HIV-1 with multidrug resistance and limited antiretroviral (ARV) options

Video player requires JavaScript enabled. You can download this video here: /content/dam/cf-viiv/rukobia-hcp/master/videos/PM-US-FST-VID-200005%20HTE%20HiRes.mp4

NOVEL MECHANISM OF ACTION

Discover a first-in-class attachment inhibitor that prevents HIV-1 from interacting with host immune cells1-3

Video player requires JavaScript enabled. You can download this video here: /content/dam/cf-viiv/rukobia-hcp/master/videos/PM-US-FST-VID-200006%20MOA%20HiRes.mp4

BRIGHTE CLINICAL TRIAL

See results from a pivotal Phase 3 trial evaluating the efficacy and safety of RUKOBIA in people living with MDR HIV-1 

Video player requires JavaScript enabled. You can download this video here: /content/dam/cf-viiv/rukobia-hcp/master/videos/PM-US-FST-VID-200007%20BRIGHTE%20Trial%20HiRes.mp4

DOSING AND DRUG INTERACTIONS

Review recommended dosing, considerations for coadministration, and contraindications with RUKOBIA

Video player requires JavaScript enabled. You can download this video here: /content/dam/cf-viiv/rukobia-hcp/master/videos/PM-US-FST-VID-200008%20Dosing%20HiRes.mp4

Downloadable Resources

Notepad

RUKOBIA PRESCRIBING INFORMATION

See the full Prescribing Information for RUKOBIA

ARV=antiretroviral.

References:

  1. Data on file, ViiV Healthcare.
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. US Department of Health and Human Services. Updated September 21, 2022. Accessed September 20, 2022. 
    https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adultadolescent-arv/guidelines-adult-adolescent-arv.pdf
  3. Cahn P, Fink V, Patterson P. Fostemsavir: a new CD4 attachment inhibitor. Curr Opin HIV AIDS. 2018;13(4):341-345.

FSTWCNT220025